<DOC>
	<DOCNO>NCT02661932</DOCNO>
	<brief_summary>The purpose study evaluate efficiency safety control ovarian stimulation ( COS ) associate aromatase inhibitor ( letrozole ) fertility preservation breast cancer patient .</brief_summary>
	<brief_title>Fertility Preservation Breast Cancer Patients</brief_title>
	<detailed_description>Patients enrol study undergo standard `` random start '' ovarian stimulation Gonadotropins use antagonist protocol begin chemotherapy . Ovulation trigger patient GnRH agonist since amendment P2015/091 ( Decapeptyl 0,2mg ) . At oocyte retrieval , aspirate follicular fluid separate flush medium hormonal assay , oocyte denude ICSI ( Intra Cytoplasmic Sperm Injection ) vitrification . Cumulus cell collect subsequent analysis oocyte quality gene expression . A . Primary objective study evaluate efficiency letrozole associate ovarian stimulation fertility preservation breast cancer patient term oocyte maturation rate . Patients ' result primary endpoint prospectively compare infertile patient undergo COS without letrozole . B . Secondary objective study aim evaluate safety protocol : 1 . Estradiol progesterone level ovulation triggering , ovulation luteal phase oocyte retrieval ( day 3 8 ) 2 . The risk disease relapse assess long-term follow-up patient ( 5 year ) well evaluation circulate tumoral DNA ovarian stimulation . 3 . Finally obstetrical outcome also record .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Breast cancer female patient less 41 year old Addressed fertility preservation Unit start chemotherapy Metastatic breast cancer Known premature ovarian failure Basal FSH &gt; 20IU Surgical contraindication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Fertility preservation</keyword>
	<keyword>letrozole</keyword>
	<keyword>Ovarian stimulation</keyword>
</DOC>